Adverum Biotechnologies, Inc.
Sümbol: ADVM
NASDAQ
10.43
USDTuruhind täna
-0.9010
P/E suhe
0.0140
PEG suhe
216.47M
MRK Cap
- 0.00%
DIV tootlus
Adverum Biotechnologies, Inc. (ADVM) Finantsaruanded
Bilanss
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 519.35 | 96.5 | 185.6 | 305.2 | ||||||||||||
balance-sheet.row.short-term-investments | 160.24 | 21.5 | 117.2 | 271 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 5.7 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 24.04 | 6.2 | 5 | 6.2 | ||||||||||||
balance-sheet.row.total-current-assets | 543.38 | 102.8 | 190.6 | 317.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 328.46 | 67 | 113.9 | 119.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 9.78 | 2 | 2.5 | 3.3 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 5.16 | 1.2 | 1.4 | 0.3 | ||||||||||||
balance-sheet.row.total-non-current-assets | 343.4 | 70.2 | 117.8 | 122.6 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 886.79 | 173 | 308.4 | 439.7 | ||||||||||||
balance-sheet.row.account-payables | 8.37 | 1.9 | 2.2 | 1.4 | ||||||||||||
balance-sheet.row.short-term-debt | 72.39 | 10.4 | 13.2 | 1.9 | ||||||||||||
balance-sheet.row.tax-payables | 0.54 | 0.1 | 0.3 | 1.3 | ||||||||||||
balance-sheet.row.long-term-debt-total | 266.93 | 64.6 | 93.6 | 101.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 33.49 | 12.5 | 16.8 | 2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 266.93 | 64.6 | 94.6 | 102.2 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 328.92 | 64.6 | 106.8 | 103 | ||||||||||||
balance-sheet.row.total-liab | 411.69 | 89.5 | 126.9 | 123.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.04 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3510.69 | -919.8 | -802.6 | -648.1 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.43 | -0.5 | -1.5 | -0.7 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3988.17 | 1003.7 | 985.7 | 965 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 475.1 | 83.5 | 181.5 | 316.2 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 886.79 | 173 | 308.4 | 439.7 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 475.1 | 83.5 | 181.5 | 316.2 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 886.79 | - | - | - | ||||||||||||
Total Investments | 162.22 | 23.5 | 117.2 | 271 | ||||||||||||
balance-sheet.row.total-debt | 339.32 | 75 | 106.8 | 103 | ||||||||||||
balance-sheet.row.net-debt | -19.78 | 0 | 38.4 | 68.8 |
Rahavoogude aruanne
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -117.17 | -117.2 | -154.5 | -145.5 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 5.64 | 5.6 | 6.5 | 4.6 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.26 | 0.4 | 0 | 3.8 | ||||||||||||
cash-flows.row.stock-based-compensation | 17.57 | 17.6 | 20.1 | 25.2 | ||||||||||||
cash-flows.row.change-in-working-capital | -8.32 | -8.3 | 19.9 | 4.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | -0.37 | -0.4 | 0.8 | -1.6 | ||||||||||||
cash-flows.row.other-working-capital | -7.95 | -7.9 | 19 | 5.7 | ||||||||||||
cash-flows.row.other-non-cash-items | 18.55 | 10.6 | -0.1 | 0 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -90.98 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.81 | -0.8 | -11.8 | -15.1 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.purchases-of-investments | -36.72 | -36.7 | -104.4 | -407.5 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 134.4 | 134.4 | 257.9 | 501.3 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 96.88 | 96.9 | 141.7 | 78.7 | ||||||||||||
cash-flows.row.debt-repayment | -2.34 | 0 | -13.6 | -0.2 | ||||||||||||
cash-flows.row.common-stock-issued | 0.49 | 0.5 | 0 | 1.7 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 1.06 | -0.4 | 14.2 | 1 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -0.72 | 0.5 | 0.6 | 2.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.54 | 0.5 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 6.72 | 6.6 | 34.2 | -26.7 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 366.91 | 75 | 70.9 | 36.7 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 360.19 | 68.4 | 36.7 | 63.4 | ||||||||||||
cash-flows.row.operating-cash-flow | -90.98 | -91.3 | -108.1 | -107.8 | ||||||||||||
cash-flows.row.capital-expenditure | -0.81 | -0.8 | -11.8 | -15.1 | ||||||||||||
cash-flows.row.free-cash-flow | -91.79 | -92.1 | -119.9 | -123 |
Kasumiaruande rida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3.6 | 3.6 | 0 | 7.5 | ||||||||||||
income-statement-row.row.cost-of-revenue | 12.58 | 5.6 | 6.5 | 4.6 | ||||||||||||
income-statement-row.row.gross-profit | -8.98 | -2 | -6.5 | 2.9 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 77.48 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 49.91 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -1.01 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 5.75 | 5.7 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.operating-expenses | 126.38 | 121.7 | 157.1 | 153.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 127.39 | 127.4 | 157.1 | 153.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.interest-expense | -1.2 | 0 | -2.7 | 0 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -1.01 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 5.55 | 5.5 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 5.75 | 5.7 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.total-operating-expenses | 5.55 | 5.5 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.interest-expense | -1.2 | 0 | -2.7 | 0 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.64 | 5.6 | 6.5 | 4.6 | ||||||||||||
income-statement-row.row.ebitda-caps | -118.15 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -123.79 | -123.8 | -157.1 | -146.1 | ||||||||||||
income-statement-row.row.income-before-tax | -118.24 | -118.2 | -154.5 | -145.5 | ||||||||||||
income-statement-row.row.income-tax-expense | -1.08 | -1.1 | 0.1 | 0 | ||||||||||||
income-statement-row.row.net-income | -117.17 | -117.2 | -154.5 | -145.5 |
Korduma kippuv küsimus
Mis on Adverum Biotechnologies, Inc. (ADVM) koguvara?
Adverum Biotechnologies, Inc. (ADVM) koguvara on 173010000.000.
Mis on ettevõtte aastane tulu?
Aastane tulu on N/A.
Mis on ettevõtte kasumimarginaal?
Ettevõtte kasumimarginaal on -2.494.
Mis on ettevõtte vaba rahavoog?
Vaba rahavoog on -9.069.
Mis on ettevõtte puhaskasumimarginaal?
Puhaskasumimarginaal on -32.546.
Mis on ettevõtte kogutulu?
Kogutulu on -34.386.
Mis on Adverum Biotechnologies, Inc. (ADVM) puhaskasum (puhaskasum)?
Puhaskasum (netotulu) on -117165000.000.
Kui suur on ettevõtte koguvõlg?
Koguvõlg on 75036000.000.
Mis on tegevuskulude arv?
Tegevuskulud on 121747000.000.
Milline on ettevõtte rahaline näitaja?
Ettevõtte raha on 75000000.000.